Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined wit… Read more
Puma Biotechnology Inc (PBYI) - Total Liabilities
Latest total liabilities as of December 2025: $85.96 Million USD
Based on the latest financial reports, Puma Biotechnology Inc (PBYI) has total liabilities worth $85.96 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Puma Biotechnology Inc - Total Liabilities Trend (2007–2025)
This chart illustrates how Puma Biotechnology Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Puma Biotechnology Inc Competitors by Total Liabilities
The table below lists competitors of Puma Biotechnology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PolEnergia S.A.
WAR:PEP
|
Poland | zł4.03 Billion |
|
SGSG Science&technology Co Ltd Zhuhai
SHE:300561
|
China | CN¥28.75 Million |
|
Wuxi Double Elephant Micro Fibre Material Co Ltd
SHE:002395
|
China | CN¥888.01 Million |
|
Kri-Kri Milk Industry S.A
AT:KRI
|
Greece | €70.41 Million |
|
Zhuhai Winbase International Chemical Tank Terminal Co Ltd
SHE:002492
|
China | CN¥572.69 Million |
|
PT Ciputra Development Tbk
F:PUWA
|
Germany | €21.73 Trillion |
|
Genesyslogic
TWO:6104
|
Taiwan | NT$1.39 Billion |
|
Foshan Electrical and Lighting Co Ltd
SHE:200541
|
China | HK$6.83 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Puma Biotechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Puma Biotechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Puma Biotechnology Inc (2007–2025)
The table below shows the annual total liabilities of Puma Biotechnology Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $85.96 Million | -29.08% |
| 2024-12-31 | $121.21 Million | -31.55% |
| 2023-12-31 | $177.09 Million | -11.66% |
| 2022-12-31 | $200.45 Million | -12.48% |
| 2021-12-31 | $229.03 Million | -8.45% |
| 2020-12-31 | $250.17 Million | +15.05% |
| 2019-12-31 | $217.44 Million | -3.28% |
| 2018-12-31 | $224.82 Million | +100.33% |
| 2017-12-31 | $112.22 Million | +161.19% |
| 2016-12-31 | $42.97 Million | +26.99% |
| 2015-12-31 | $33.84 Million | -25.98% |
| 2014-12-31 | $45.71 Million | +124.21% |
| 2013-12-31 | $20.39 Million | -10.54% |
| 2012-12-31 | $22.79 Million | +2122.04% |
| 2011-12-31 | $1.03 Million | +45082.03% |
| 2009-12-31 | $2.27K | +0.93% |
| 2008-12-31 | $2.25K | -99.84% |
| 2007-12-31 | $1.41 Million | -- |